Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

April 19, 2022 by Alan Khadavi

Asivatrep a new topical treatment for Eczema

Asivatrep is a new potential treatment for eczema (atopic dermatitis). Atopic dermatitis is a chronic inflammatory itchy skin disease that affects up to 25% of children and 10% of adults. The cause is complex and multifactorial. Currently there are few classes of topical medications to treat it.

  1. Steroids
  2. Calcineurin inhibitors (Elidel, Protopic)
  3. Phosphodiesterase 4 inhibitors Eucrisa (crisaborole) New Eczema Medication gets FDA Approval
  4. JAK inhibitors Opzelura (ruxolitinib) for Eczema

Long term use of topical steroids may lead to skin adverse reactions, such as thinning of the skin and telangiectasia.

Calcineurin inhibitors can cause irritation, burning, and stinging at the application site.

The transient receptor vanilloid subfamily V member 1 (TRPV1), is a nonselective cation channel, that is expressed in many cells that may an important role in skin physiology and disease. TRPV1 is involved in inflammation and plays a role in signaling in patients with eczema. TRPV1 increases peptides that play a role in itching and it is overexpressed in skin lesions of atopic dermatitis, and its activation results in the release of molecules that enhance itching and inflammation. Inhibiting TRPV1 may be an option to treat eczema.

Asivatrep cream 1% is a TRPV1 antagonist used to treat mild to moderate eczema. Early studies showed that it reduced skin inflammation. A phase 3 study published in the Journal of Allergy and Clinical Immunology titled “Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: Phase 3, randomized, vehicle-controlled study (CAPTAIN-AD), showed the following results.

  • The Asivatrep had significantly greater improvements in IGA (Investigator’s Global Assessment).
  • The mean percentage reduction in the Eczema Area and Severity Index (EASI) was 44% vs 21%, in Asivatrep vs vehicle, respectively.
  • More Asivatrep experienced larger improvements using the EASI scale compared to vehicle.

No significant safety issues were reported.

Asivatrep cream showed greater improvement in clinical signs of eczema by IGA, EASI and itching compared to the vehicle. This topical TRPV1 antagonist is a promising topical medication for patients with atopic dermatitis.

Filed Under: atopic dermatitis, Blog, Medications

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

March 16, 2023

Does an Air Purifier help Asthma?

air purifier help asthma

March 13, 2023

Tezspire vs. Nucala vs. Fasenra vs. Dupixent for Eosinophilic Asthma, a comparison

Tezspire vs. Nucala vs. Fasenra vs. Dupixent

February 16, 2023

Cucumber Allergy can come in many flavors

cucumber allergy

February 10, 2023

Do Allergy Shots help Eczema?

Can allergy shots help eczema?

January 22, 2023

Is Benadryl Safe to use, or is it Time to Move on?

is benadryl safe

January 12, 2023

Airsupra for Asthma, a new rescue medication

airsupra

December 26, 2022

Cantaloupe Allergy comes in many flavors

cantaloupe allergy

December 23, 2022

Remibrutinib, a BTK inhibitor for Chronic Hives

remibrutininb

November 21, 2022

Eczema and Hard Water, is there a link?

eczema and hard water

November 19, 2022

Nucala, Fasenra or Dupixent for Severe Eosinophilic Asthma?

nucala fasenra dupixent

Read More Posts...

Follow Us…

© 2023 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page